RxDoctor Payments Data

Kristen Ayrer

Gerontology · Langhorne, PANPI 1083249072

Payments from drug & device makers

$1,499in general payments, 2019–2025

Across 69 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$339
  • Lilly USA, LLC$216
  • Novo Nordisk$206
  • Sanofi-aventis U.S. LLC$135
  • Corcept Therapeutics$120
  • Dexcom, Inc.$115
  • plus $367 from 12 others

What the payments were for

  • Food & beverage$1,48799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,499 in reported general payments places this provider in the 80th percentile of 383 gerontology providers in Pennsylvania.

See all gerontology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,865
Medicare patients
173
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$73,309
MounjaroTirzepatide49$72,157
TrulicityDulaglutide30$41,102
FarxigaDapagliflozin Propanediol19$24,778
JardianceEmpagliflozin27$22,422
JanuviaSitagliptin Phosphate14$17,747
Tresiba Flextouch U-100Insulin Degludec14$9,416
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,129
Novolog FlexpenInsulin Aspart17$4,615
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$1,910
Glimepiride33$572
Levothyroxine Sodium27$464
Repaglinide14$369
Metformin Hcl ErMetformin Hcl14$360
Glipizide ErGlipizide15$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$216$113,26079 claims
Novo NordiskOzempic$206$73,30944 claims
AstraZenecaFarxiga$339$24,77819 claims
Boehringer IngelheimJardiance$15$22,42227 claims
MerckJanuvia$13$17,74714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 383 gerontology providers in Pennsylvania.

Other gerontology in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →